Artiva Biotherapeutics, Common Stock Current Valuation
| ARTV Stock | 6.53 0.25 3.69% |
Valuation analysis of Artiva Biotherapeutics, helps investors to measure Artiva Biotherapeutics,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -2.52 in 2025. Enterprise Value Multiple is likely to drop to -2.52 in 2025. Fundamental drivers impacting Artiva Biotherapeutics,'s valuation include:
Undervalued
Today
Please note that Artiva Biotherapeutics,'s price fluctuation is slightly risky at this time. Calculation of the real value of Artiva Biotherapeutics, is based on 3 months time horizon. Increasing Artiva Biotherapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Artiva stock is determined by what a typical buyer is willing to pay for full or partial control of Artiva Biotherapeutics, Common. Since Artiva Biotherapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Artiva Stock. However, Artiva Biotherapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.53 | Real 10.08 | Target 21.0 | Hype 6.31 |
The intrinsic value of Artiva Biotherapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Artiva Biotherapeutics,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Artiva Biotherapeutics, Common helps investors to forecast how Artiva stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Artiva Biotherapeutics, more accurately as focusing exclusively on Artiva Biotherapeutics,'s fundamentals will not take into account other important factors: Artiva Biotherapeutics, Common Company Current Valuation Analysis
Artiva Biotherapeutics,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Artiva Biotherapeutics, Current Valuation | 26.95 M |
Most of Artiva Biotherapeutics,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artiva Biotherapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Artiva Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Artiva Biotherapeutics, is extremely important. It helps to project a fair market value of Artiva Stock properly, considering its historical fundamentals such as Current Valuation. Since Artiva Biotherapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artiva Biotherapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artiva Biotherapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Artiva Biotherapeutics, Common has a Current Valuation of 26.95 M. This is 99.81% lower than that of the Biotechnology sector and 99.42% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.84% higher than that of the company.
Artiva Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artiva Biotherapeutics,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artiva Biotherapeutics, could also be used in its relative valuation, which is a method of valuing Artiva Biotherapeutics, by comparing valuation metrics of similar companies.Artiva Biotherapeutics, is currently under evaluation in current valuation category among its peers.
Artiva Fundamentals
| Return On Equity | -0.44 | ||||
| Operating Margin | (23.45) % | ||||
| Current Valuation | 26.95 M | ||||
| Shares Outstanding | 24.29 M | ||||
| Shares Owned By Insiders | 20.64 % | ||||
| Shares Owned By Institutions | 89.12 % | ||||
| Number Of Shares Shorted | 1.17 M | ||||
| Price To Book | 0.79 X | ||||
| Price To Sales | 60.98 X | ||||
| Revenue | 33.49 M | ||||
| Gross Profit | 2.6 M | ||||
| EBITDA | (28.41 M) | ||||
| Net Income | (28.72 M) | ||||
| Total Debt | 16.91 M | ||||
| Book Value Per Share | 8.28 X | ||||
| Cash Flow From Operations | (47.43 M) | ||||
| Short Ratio | 18.02 X | ||||
| Earnings Per Share | (2.48) X | ||||
| Target Price | 21.0 | ||||
| Number Of Employees | 82 | ||||
| Market Capitalization | 158.61 M | ||||
| Total Asset | 105.11 M | ||||
| Retained Earnings | (181.31 M) | ||||
| Working Capital | 67.59 M | ||||
| Net Asset | 105.11 M |
About Artiva Biotherapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artiva Biotherapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artiva Biotherapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artiva Biotherapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.